Acorda Therapeutics (ACOR) Misses Q1 EPS by 17c

Acorda Therapeutics (NASDAQ: ACOR) reported Q1 EPS of ($0.08), $0.17 worse than the analyst estimate of $0.09. Revenue for the quarter came in at $119.4 million versus the consensus estimate of $127.34 million.

• Corporate restructuring implemented to focus on late-stage Parkinson’s programs
• 2017 combined R&D and SG&A operating expense guidance revised to $330 - $350 million, a reduction of ~$50 million
• Projected year-end cash balance greater than $200 million
• AMPYRA® (dalfampridine) 1Q 2017 net revenue of $112.0 million; Company reiterates AMPYRA net sales guidance of $535 - $545 million

For earnings history and earnings-related data on Acorda Therapeutics (ACOR) click here.

You May Also Be Interested In

• Flowers Foods (FLO) Misses Q2 EPS by 3c; Offers Guidance
• Opera Limited (OPRA) Misses Q2 EPS by 1c ; Offers Guidance
• Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance